J Breast Dis.  2018 Dec;6(2):46-51. 10.14449/jbd.2018.6.2.46.

Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

• Kim SH
• Choi J
• Park CS
• Kim HA
• Noh WC
• Seong MK

• KMID: 2434904
• DOI: http://doi.org/10.14449/jbd.2018.6.2.46

Abstract

PURPOSE
Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC.
METHODS
We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy.
RESULTS
The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity.
CONCLUSION
Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.

Keyword

Aromatase inhibitors; Breast neoplasms; Gonadotropin-releasing hormone; Goserelin; Premenopause

MeSH Terms

Aromatase Inhibitors
Aromatase*
Breast Neoplasms*
Breast*
Follow-Up Studies
Gonadotropin-Releasing Hormone*
Goserelin
Humans
Lutein*
Medical Records
Premenopause
Retrospective Studies
Aromatase
Aromatase Inhibitors
Gonadotropin-Releasing Hormone
Goserelin
Lutein